A Beta-only IL-2 ImmunoTherapY Study
← catalyst calendarSponsored by Medicenna Therapeutics, Inc. (industry) · MDNAF — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
115estimated
Sites
27
Countries
Australia, Canada, Ireland +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-08-27 | actual | When the study began enrolling |
| Primary completion | 2026-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Unresectable Solid Tumor
- Clear Cell Renal Cell Carcinoma
- Triple Negative Breast Cancer
- Non-Small Cell Lung Cancer Squamous
- Non-Small Cell Lung Cancer Non-squamous
- Colorectal Cancer (MSI-H)
- Gastric Cancer
- Cervical Cancer
- Basal Cell Carcinoma
- Bladder Cancer
- Merkel Cell Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Cutaneous Squamous Cell Carcinoma
- Pleural Mesothelioma
- Esophageal Cancer
- Endometrial Carcinoma
- Solid Tumor
- Solid Tumor, Adult
- MSI-H Solid Malignant Tumor
- Cancer With A High Tumor Mutational Burden
- Epithelial Ovarian Carcinoma
- Primary Peritoneal Cancer
- Gastroesophageal Junction (GEJ) Cancer
- Acral Melanoma
- Mucosal Melanoma
- Cutaneous Melanoma
- DMMR Solid Malignant Tumor
- Fallopian Tube Cancer
- Ovarian Cancer
- MSI-H Cancer
- DMMR Cancer
- Pancreas Adenocarcinoma (MSI-H)
- Skin Cancer
- Viral Cancer
- Cervical Cancers
- Endometrial Cancer
Interventions
- Drug: MDNA11 — also filed as Interleukin-2 (IL-2)-albumin
- Drug: Pembrolizumab (KEYTRUDA®)
Primary outcomes
what the primary-completion date above is the date OFMDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE)
measured 24 months
Incidence of Treatment Related Adverse Events (TRAEs)
measured 24 months
Incidence of Treatment Emergent Adverse Events (TEAEs)
measured 24 months
Permalink · MDNAF's whole pipeline · Catalyst calendar · Every registered study · What changed